Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Meng Li, Hong Zhao, Xiaosong Zhang, Laura D. Wood, Robert A. Anders, Michael A. Choti, Timothy M. Pawlik, Hubert D. Daniel, Rajesh Kannangai, G. Johan A Offerhaus, Victor E. Velculescu, Linfang Wang, Shibin Zhou, Bert Vogelstein, Ralph H. Hruban, Nick Papadopoulos, Jianqiang Cai, Michael S. Torbenson, Kenneth W. Kinzler

Research output: Contribution to journalArticlepeer-review

342 Scopus citations


Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

Original languageEnglish (US)
Pages (from-to)828-829
Number of pages2
JournalNature genetics
Issue number9
StatePublished - Sep 2011

ASJC Scopus subject areas

  • Genetics


Dive into the research topics of 'Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this